Hosted on MSN1mon
AbbVie acquires Nimble Therapeutics to boost R&DAbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical ... has announced the completion of its acquisition of Nimble Therapeutics, a move aimed at strengthening its research and development pipeline ...
Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...
Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...
Last month, AbbVie completed its acquisition of Nimble Therapeutics, and it also announced a partnership with Simcere Zaiming and expanded its collaboration with AbCellera. A stock popular with ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...
a Represents net earnings (loss) attributable to AbbVie Inc. Intangible asset impairment ... intangible asset acquired as part of the Cerevel Therapeutics acquisition. Income tax items primarily ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results